(Reuters) - "This is a bit of a unique situation because, on the one hand, ) Gardasil is on the market, so there is no reason on that count for an accelerated review, but on the other hand we have some unique characteristics for this vaccine."
Glaxo hopes to launch Cervarix in Europe and international markets this year but analysts say it will only get to market in the United States later, unless the FDA grants a priority review.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment